Certara (NASDAQ:CERT) Stock Price Expected to Rise, Barclays Analyst Says

Certara (NASDAQ:CERT - Get Free Report) had its price target hoisted by analysts at Barclays from $12.00 to $13.00 in a note issued to investors on Friday,Benzinga reports. The brokerage presently has an "equal weight" rating on the stock. Barclays's target price points to a potential upside of 9.70% from the company's previous close.

Several other equities research analysts have also recently commented on the company. Robert W. Baird cut their target price on Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a research note on Tuesday, November 5th. TD Cowen started coverage on shares of Certara in a report on Thursday, February 27th. They set a "buy" rating and a $16.00 target price for the company. Stephens reiterated an "overweight" rating and issued a $17.00 price target on shares of Certara in a research note on Thursday, February 27th. Finally, William Blair restated a "market perform" rating on shares of Certara in a report on Thursday, February 27th. Four investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $15.83.

Remove Ads

Certara Stock Down 0.8 %

Shares of Certara stock traded down $0.09 during trading on Friday, reaching $11.85. The stock had a trading volume of 1,434,553 shares, compared to its average volume of 967,339. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $1.91 billion, a price-to-earnings ratio of -59.25, a P/E/G ratio of 9.29 and a beta of 1.57. The stock has a fifty day moving average price of $12.48 and a two-hundred day moving average price of $11.63. Certara has a 52 week low of $9.41 and a 52 week high of $19.87.

Institutional Trading of Certara

Several institutional investors have recently added to or reduced their stakes in CERT. ArrowMark Colorado Holdings LLC increased its holdings in shares of Certara by 164.2% during the fourth quarter. ArrowMark Colorado Holdings LLC now owns 6,213,278 shares of the company's stock worth $66,171,000 after purchasing an additional 3,861,674 shares during the period. Ameriprise Financial Inc. grew its holdings in shares of Certara by 864.0% during the 4th quarter. Ameriprise Financial Inc. now owns 3,779,655 shares of the company's stock worth $40,253,000 after purchasing an additional 3,387,590 shares in the last quarter. Brown Brothers Harriman & Co. bought a new position in shares of Certara in the third quarter worth $27,292,000. Mackenzie Financial Corp acquired a new position in Certara in the fourth quarter valued at about $17,852,000. Finally, Wasatch Advisors LP raised its stake in Certara by 22.4% in the third quarter. Wasatch Advisors LP now owns 9,015,941 shares of the company's stock valued at $105,577,000 after purchasing an additional 1,651,076 shares in the last quarter. 73.96% of the stock is currently owned by institutional investors.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.